Patents Examined by Mukund J. Shah
  • Patent number: 6846818
    Abstract: The present invention relates to cyclooxygenase-2 (COX-2) selective inhibitors of formula I: pharmaceutical compositions containing them, to their medicinal use, and to their preparations. The compounds of the invention are particularly useful in the treatment or alleviation of inflammation and inflammation associated disorders, such as, for example, rheumatoid arthritis and osteoarthritis, and in the relief of pain, such as, for example, pain associated with surgery or trauma, in mammals, preferably felines and canines.
    Type: Grant
    Filed: April 16, 2003
    Date of Patent: January 25, 2005
    Assignee: Pfizer Inc.
    Inventors: Kristin Lundy DeMello, Brian S. Bronk, Rhonda Marie Crosson
  • Patent number: 6844338
    Abstract: A pharmaceutical compound of the formula (I) in which R1 and R2 are each hydrogen or C1-6 alkyl, R3 is —SR10, —SOR10, —SO2R10, —COR10, —CH2OH or —CONHR11, where R10 is C1-6 alkyl and R11 is hydrogen or C1-6 alkyl, R4, R5, R6 and R7 are each hydrogen or C1-6alkyl, provided that at least one of R4, R5, R6 and R7 is C1-6alkyl, R8 and R9 are each hydrogen, halo, C1-6 alkyl or cyano, n is 0 or 1 and m is 2 or 3, x is a (a) or (b), and y is (c) or (d), wherein R12 and R13 are each hydrogen, C1- alkyl, cyclopropyl or cyclopropyl-C1-6 alkyl; and salts thereof.
    Type: Grant
    Filed: May 4, 2001
    Date of Patent: January 18, 2005
    Assignee: Eli Lilly and Company
    Inventors: John Fairhurst, Peter Gallagher
  • Patent number: 6844340
    Abstract: The present invention relates to tricyclic 2-pyrimidone compounds of formula (I): or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HIV reverse transcriptase, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.
    Type: Grant
    Filed: January 17, 2003
    Date of Patent: January 18, 2005
    Assignee: Bristol-Myers Squibb Company
    Inventor: Christine M. Tarby
  • Patent number: 6841668
    Abstract: Sterically hindered N-substituted aryloxyamines are prepared by the Keggin polyoxometalate or the transition metal substituted polyoxometalate (TMS-POM) catalyzed decomposition of diazonium salts in the presence of a sterically hindered nitoxyl radical. These compounds are useful as thermal and light stabilizers for a variety of organic substrates.
    Type: Grant
    Filed: April 4, 2003
    Date of Patent: January 11, 2005
    Assignee: Ciba Specialty Chemicals Corporation
    Inventors: Deborah Judd, Sai P. Shum, Stephen D. Pastor
  • Patent number: 6821978
    Abstract: A xanthine phosphodiesterase V inhibitor having the formula (I), with the variables defined herein, which is especially useful for treating male (erectile) and female sexual dysfunction and other physiological disorders: For example, a representative compound of the invention is:
    Type: Grant
    Filed: August 28, 2001
    Date of Patent: November 23, 2004
    Assignee: Schering Corporation
    Inventors: Samuel Chackalamannil, Yuguang Wang, Craig D. Boyle, Andrew W. Stamford
  • Patent number: 6818450
    Abstract: The present invention is directed to an analytical method for measuring the concentration of an N-(phosphonomethyl)iminodiacetic acid (“NPMIDA”) substrate, an N-(phosphonomethyl)glycine product, formaldehyde, formic acid, N-methyl-N-(phosphonomethyl)glycine (“NMG”), N-methyl-aminomethylphosphonic acid (MAMPA) or aminomethylphosphonic acid (“AMPA”)) in an aqueous mixture thereof, using infrared spectroscopy. The present invention is also directed to a process for oxidizing an N-(phosphonomethyl)iminodiacetic acid substrate to form a N-(phosphonomethyl)glycine product, and as part of the process, measuring the concentration of at least one reactant, product or byproduct of the oxidation reaction using the analytical method of the present invention and controlling the oxidation process in response to the measurement taken.
    Type: Grant
    Filed: May 17, 2002
    Date of Patent: November 16, 2004
    Assignee: Monsanto Technology LLC
    Inventors: David R. Eaton, Walter Gavlick, Gary Klopf, Arnold Hershman, Denis Forster
  • Patent number: 6809097
    Abstract: Compounds of the formula (I): wherein: R2 represents hydroxy, halogeno, C1-3alkyl, C1-3alkoxy, C1-3alkanoyloxy, trifluoromethyl, cyano, amino or nitro; n is an integer from 0 to 5; Z represents —O—, —NH—, —S— or —CH2—; G1 represents phenyl or a 5-10 membered heteroaromatic cyclic or bicyclic group; Y1, Y2, Y3 and Y4 each independently represents carbon or nitrogen; R1 represents fluoro or hydrogen; m is an integer from 1 to 3; R3 represents hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, C1-3alkyl, —NR4R5 (wherein R4 and R5, can each be hydrogen or C1-3alkyl), or a group R6—X1— wherein X1 represents —CH2— or a heteroatom linker group and R6 is an alkyl, alkenyl or alkynyl chain optionally substituted by for example hydroxy, amino, nitro, alkyl, cycloalkyl, alkoxyalkyl, or an optionally substituted group selected from pyridone, phenyl and a heterocyclic ring, which alkyl, alkenyl or alkynyl chain may hav
    Type: Grant
    Filed: March 9, 1999
    Date of Patent: October 26, 2004
    Assignees: Zeneca Limited, Zeneca Pharma S.A.
    Inventors: Andrew Peter Thomas, Laurent Francois Andre Hennequin, Patrick Ple
  • Patent number: 6809098
    Abstract: The present invention relates to compounds of formula I which are antagonists of gonadotropin releasing hormone (GnRH) activity. The invention also relates to pharmaceutical formulations, the use of a compound of the present invention in the manufacture of a medicament, a method of therapeutic treatment using such a compound and processes for producing the compounds.
    Type: Grant
    Filed: August 21, 2002
    Date of Patent: October 26, 2004
    Assignee: AstraZeneca AB
    Inventors: Michael Wardleworth, Alexander Graham Dossetter, Christopher Thomas Halsall
  • Patent number: 6806391
    Abstract: Process for the carbonylation of optionally substituted ethylenically unsaturated compounds by reaction with carbon monoxide and a coreactant in the presence of a catalyst system. The catalyst system includes (a) a source of Pt group metal cations, (b) a certain bidentate diphosphine composition.
    Type: Grant
    Filed: July 31, 2002
    Date of Patent: October 19, 2004
    Assignee: Shell Oil Company
    Inventor: Eit Drent
  • Patent number: 6800633
    Abstract: This invention pertains to compounds having the structure: wherein R1 and R2 are each independently a hydrogen atom, substituted alkyl, or a substituted or unsubstituted aryl, or alkylaryl moiety or together form a substituted or unsubstituted heterocyclic ring, provided that both R1 and R2 are both not hydrogen atoms or that neither R1 or R2 is 1-phenylethyl; R3 is a substituted or unsubstituted aryl, or alkylaryl moiety; R4 is a hydrogen atom or a substituted or unsubstituted alkyl, aryl, or alkylaryl moiety; and R5 and R6 are each independently a halogen atom, a hydrogen atom or a substituted or unsubstituted alkyl, aryl, or alkylaryl moiety, and the use of these compounds to treat a disease associated with increased levels of adenosine in a subject.
    Type: Grant
    Filed: December 1, 2000
    Date of Patent: October 5, 2004
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: Arlindo L. Castelhano, Bryan McKibben, David J. Witter
  • Patent number: 6797706
    Abstract: A nitrogen-containing six-membered heterocyclic compound having substituents —X—A—R3, —N(R1)-(Ph substituted by R2), and —CONH2, a salt thereof, a prodrug thereof, and a Syk inhibitor containing the same as an active ingredient. (In the formula, A: a (substituted) lower alkylene, a (substituted) arylene, or the like; X: NR4, CONR4, NR4CO, O, or S; R1, R4: H, a lower alkyl, —CO-lower alkyl, or —SO2-lower alkyl; R2: H, a (substituted) lower alkyl, —O-lower alkyl, —S-lower alkyl, —O-aryl, nitro, cyano, or the like; R3: —CO2H, —CO2-lower alkyl, -lower alkylene-CO2H, —NH2, -alkylene-NH2 or the like.
    Type: Grant
    Filed: December 10, 2001
    Date of Patent: September 28, 2004
    Assignee: Yamanouchi Pharmaceutical Co., Ltd.
    Inventors: Hiroyuki Hisamichi, Souichirou Kawazoe, Kazuhito Tanabe, Atsushi Ichikawa, Akiko Orita, Takayuki Suzuki, Kenichi Onda, Makoto Takeuchi
  • Patent number: 6794381
    Abstract: This invention relates to novel lactams having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A&bgr;-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to &bgr;-amyloid production such as Alzheimer's disease and Down's Syndrome.
    Type: Grant
    Filed: February 17, 2000
    Date of Patent: September 21, 2004
    Assignee: Bristol-Myers Squibb Company
    Inventors: Richard E. Olson, Thomas P. Maduskuie, Lorin Andrew Thompson
  • Patent number: 6790844
    Abstract: Condensed pyridine compounds represented by formula (I): wherein: R1 and R3 are, independently, hydrogen, halogen, lower alkyl, or lower alkoxy; R2 represents an amino substituent; ring A is a benzene ring, pyridine ring, thiophene ring, or furan ring; and B represents a substituent containing a ring structure. Also, pharmaceutically acceptable salt and hydrates thereof. These compounds are clinically useful medicaments having; serotonin antagonism, and in particular, for treating, ameliorating, or preventing spastic paralysis. They are also useful as central muscle relaxants for ameliorating myotonia.
    Type: Grant
    Filed: May 11, 2001
    Date of Patent: September 14, 2004
    Assignee: Eisai Co., Ltd
    Inventors: Kohshi Ueno, Atsushi Sasaki, Koki Kawano, Tadashi Okabe, Noritaka Kitazawa, Keiko Takahashi, Noboru Yamamoto, Yuichi Suzuki, Manabu Matsunaga, Atsuhiko Kubota
  • Patent number: 6787542
    Abstract: The present invention relates to novel heterocyclyl-containing diaryl sulfide compounds that are useful for treating inflammatory and immune diseases, to pharmaceutical compositions comprising these compounds, and to methods of inhibiting inflammation or suppressing immune response in a mammal.
    Type: Grant
    Filed: June 25, 2001
    Date of Patent: September 7, 2004
    Assignee: ICOS Corporation
    Inventors: Gary T. Wang, Sheldon Wang, Robert Gentles
  • Patent number: 6787541
    Abstract: Compounds of formula (I): wherein X is S. Compounds can be used for treating a disorder in which the blocking of purine receptors is beneficial.
    Type: Grant
    Filed: March 13, 2002
    Date of Patent: September 7, 2004
    Assignee: Vernalis Research Limited
    Inventors: Roger John Gillespie, Joanne Lerpiniere, Paul Richard Giles, Claire Elizabeth Dawson, David Bebbington
  • Patent number: 6787653
    Abstract: A process for preparing a biphenylcarboxylic acid amide derivative represented by the following formula (1): wherein, R1, R2 and R3 each independently represents a hydrogen atom or a substituent, which comprises reacting, in the presence of a metal catalyst, a halogenobenzoic acid derivative represented by the following formula (2): wherein, X represents a halogen atom with a compound represented by the following formula (3): wherein, R1, R2 and R3 have the same meanings as described above, and Y represents an leaving group having an element selected from the group consisting of boron, silicon, zinc, tin and magnesium; or salt thereof. According to the present invention, biphenylcarboxylic acid amide derivatives of the formula (1) or salts thereof having excellent inhibitory activity against IgE antibody production can be prepared by the reduced number of steps, conveniently, at lower cost and in a high yield.
    Type: Grant
    Filed: June 6, 2002
    Date of Patent: September 7, 2004
    Assignee: Kowa Co., Ltd.
    Inventors: Hiroyuki Ishiwata, Seiichi Sato, Mototsugu Kabeya, Soichi Oda
  • Patent number: 6784200
    Abstract: The present application describes modulators of CCR3 of formula (I): A—E—NR1—G  (I) or pharmaceutically acceptable salt forms thereof, useful for the prevention of inflammatory diseases such as asthma and other allergic diseases.
    Type: Grant
    Filed: May 1, 2003
    Date of Patent: August 31, 2004
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: John V Duncia, Joseph B Santella, III, Daniel S Gardner, Dean A Wacker
  • Patent number: 6784182
    Abstract: Compounds of formula (I) in which R2, X, Y, Cy, L and Lp(D)n have the meanings given in the specification, are inhibitors of the serine protease, factor Xa and are useful in the treatment of cardiovascular disorders.
    Type: Grant
    Filed: February 4, 2002
    Date of Patent: August 31, 2004
    Assignee: Eli Lilly and Company
    Inventors: John Walter Liebeschuetz, Christopher William Murray, Stephen Clinton Young, Nicholas Paul Camp, Stuart Donald Jones, William Alexander Wylie, John Joseph Masters, Michael Robert Wiley, Scott Martin Sheehan, David Birenbaum Engel, Brian Morgan Watson
  • Patent number: 6780993
    Abstract: A method for preparing 1-C-(9-deazaaden-9-yl)-1,4-imino-D-5′-deoxy-5′-methylthiorbitol) and pharmaceutically acceptable salts thereof is provided.
    Type: Grant
    Filed: February 19, 2003
    Date of Patent: August 24, 2004
    Assignee: BioCryst Pharmaceuticals, Inc.
    Inventors: Vivekanand Kamath, Philip E. Morris, Jr.
  • Patent number: 6780856
    Abstract: The invention relates to methods of stabilizing in an aqueous medium cobalt (III) Schiff base complexes and stabilized cobalt (III) Schiff base compounds therefrom.
    Type: Grant
    Filed: April 6, 2001
    Date of Patent: August 24, 2004
    Assignee: California Institute of Technology
    Inventors: Thomas J. Meade, Ofer Blum, Harry B. Gray